Objectives The United Parkinson’s Disease Rating Scale (UPDRS) for motor skills testing has been the primary tool for diagnosing Parkinson’s disease. Recently, DaTscan has been introduced as an ...

Objectives In 2011, FDA approved DaTscan Ioflupane I-123 injection with SPECT imaging for differentiating patients with Parkinsonian syndromes or essential tremor. DaTscan measures the concentration ...

Guelph Medical Imaging (GMI) says a new exam now available at its clinic on Dawson Road is able to definitively tell patients if they have Parkinsonian Syndromes, such as Parkinson’s Disease. DaTscan ...

DaTscan is first radiopharmaceutical diagnostic tracer approved by U.S. FDA for use in patients with suspected Dementia with Lewy Bodies (DLB) Builds on DaTscan market leadership globally with over ...

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...

GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...

PRINCETON, N.J., Jan. 14, 2011 /PRNewswire/ -- GE Healthcare announced today the US Food and Drug Administration (FDA) has approved DaTscan (Ioflupane I 123 Injection), a radiopharmaceutical agent ...

DaTscan is first radiopharmaceutical diagnostic tracer approved by U.S. FDA for use in patients with suspected Dementia with Lewy Bodies (DLB) Builds on DaTscan market leadership globally with over ...

GE Healthcare’s DaTscan has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB). DaTscan is first radiopharmaceutical ...